Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
14 févr. 2023 08h00 HE
|
Royal Biologics
HACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Royal Biologics, a company specializing in Advanced Cellular Technologies & Enhanced Autologous Solutions, today announces the commercial...
Royal Biologics Announces FDA 510K Approval and U.S. Commercial Launch of the MAXX™-BMC Bone Marrow Aspirate Concentration System
01 juin 2022 09h00 HE
|
Royal Biologics
HACKENSACK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Royal Biologics (Hackensack, NJ), a company specializing in Advanced Cellular Technologies & Enhanced Autologous Healing, announces today the...
Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
08 sept. 2021 09h12 HE
|
Royal Biologics
HACKENSACK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP...
Royal Biologics Announces the Launch of Cryo-Cord™, the First Non-DMSO Viable Umbilical Cord Graft
21 janv. 2020 11h13 HE
|
Royal Biologics
HACKENSACK, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company specializing in the research and advancement of novel ortho-biologics solutions, today announced the...
Royal Biologics Launches MAGNUS, a DMSO-free Viable Cellular Bone Allograft
09 janv. 2020 09h00 HE
|
Royal Biologics
HACKENSACK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Royal Biologics, an orthobiologics company specializing in the research and advancement of regenerative cellular therapy and novel orthobiologic...